BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 137 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $74,101,956 | -14.2% | 10,466,378 | -14.7% | 0.00% | -20.0% |
Q2 2023 | $86,338,342 | -9.1% | 12,263,969 | +7.7% | 0.01% | 0.0% |
Q1 2023 | $94,989,576 | -62.8% | 11,389,623 | -48.8% | 0.01% | -37.5% |
Q4 2022 | $255,472,728 | +115.6% | 22,253,722 | +136.6% | 0.01% | +14.3% |
Q3 2022 | $118,494,000 | +1.8% | 9,404,247 | -14.5% | 0.01% | 0.0% |
Q2 2022 | $116,431,000 | -4.0% | 11,004,803 | +47.5% | 0.01% | +16.7% |
Q1 2022 | $121,344,000 | +6.2% | 7,462,752 | -9.5% | 0.01% | +20.0% |
Q4 2021 | $114,249,000 | +11.9% | 8,249,029 | +16.1% | 0.01% | 0.0% |
Q3 2021 | $102,103,000 | +3.3% | 7,105,323 | +13.6% | 0.01% | 0.0% |
Q2 2021 | $98,856,000 | +33.0% | 6,252,772 | -14.4% | 0.01% | +25.0% |
Q1 2021 | $74,331,000 | -9.8% | 7,308,816 | -33.9% | 0.00% | -20.0% |
Q4 2020 | $82,374,000 | +48.2% | 11,056,979 | -31.7% | 0.01% | +25.0% |
Q3 2020 | $55,592,000 | -25.1% | 16,183,973 | +3.9% | 0.00% | -20.0% |
Q2 2020 | $74,231,000 | +545.9% | 15,578,395 | +171.1% | 0.01% | +400.0% |
Q1 2020 | $11,492,000 | -39.4% | 5,746,052 | +4.6% | 0.00% | 0.0% |
Q4 2019 | $18,951,000 | +36.1% | 5,492,943 | +13.0% | 0.00% | 0.0% |
Q3 2019 | $13,929,000 | -44.7% | 4,861,776 | -26.8% | 0.00% | -50.0% |
Q2 2019 | $25,187,000 | -11.8% | 6,645,717 | +89.3% | 0.00% | 0.0% |
Q1 2019 | $28,572,000 | +26.6% | 3,510,042 | +25.5% | 0.00% | 0.0% |
Q4 2018 | $22,571,000 | -12.9% | 2,796,960 | -17.6% | 0.00% | 0.0% |
Q3 2018 | $25,909,000 | +23.0% | 3,395,701 | -7.7% | 0.00% | 0.0% |
Q2 2018 | $21,072,000 | -2.0% | 3,677,404 | -18.4% | 0.00% | 0.0% |
Q1 2018 | $21,494,000 | +12.4% | 4,504,714 | +15.7% | 0.00% | 0.0% |
Q4 2017 | $19,120,000 | +23.0% | 3,894,547 | +31.2% | 0.00% | +100.0% |
Q3 2017 | $15,545,000 | -28.5% | 2,967,585 | -24.1% | 0.00% | -50.0% |
Q2 2017 | $21,736,000 | +13.9% | 3,909,013 | +72.0% | 0.00% | 0.0% |
Q1 2017 | $19,083,000 | +44.1% | 2,272,104 | +8.6% | 0.00% | +100.0% |
Q4 2016 | $13,246,000 | +122.8% | 2,092,888 | +55.2% | 0.00% | 0.0% |
Q3 2016 | $5,945,000 | +56.3% | 1,348,308 | +0.7% | 0.00% | – |
Q2 2016 | $3,803,000 | +0.0% | 1,339,348 | -0.3% | 0.00% | – |
Q1 2016 | $3,802,000 | -82.6% | 1,343,332 | -36.5% | 0.00% | -100.0% |
Q4 2015 | $21,823,000 | -39.3% | 2,114,768 | -32.9% | 0.00% | -50.0% |
Q3 2015 | $35,938,000 | -25.0% | 3,152,313 | -1.8% | 0.00% | -20.0% |
Q2 2015 | $47,927,000 | +58.9% | 3,210,208 | -3.9% | 0.01% | +66.7% |
Q1 2015 | $30,171,000 | -11.1% | 3,341,212 | +19.7% | 0.00% | 0.0% |
Q4 2014 | $33,933,000 | +48.8% | 2,790,435 | +19.7% | 0.00% | +50.0% |
Q3 2014 | $22,811,000 | -20.4% | 2,332,066 | +3.8% | 0.00% | -33.3% |
Q2 2014 | $28,653,000 | +65.3% | 2,247,454 | +37.2% | 0.00% | +50.0% |
Q1 2014 | $17,334,000 | +1124.2% | 1,638,419 | +121.2% | 0.00% | – |
Q4 2013 | $1,416,000 | +296.6% | 740,687 | +1412.1% | 0.00% | – |
Q3 2013 | $357,000 | +457.8% | 48,984 | +18.7% | 0.00% | – |
Q2 2013 | $64,000 | – | 41,284 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |